


Oncology Molecular Diagnostics Market Trends: How Competition Is Reshaping Industry Structure

*The Business Research Company's
Oncology Molecular Diagnostics Market
Report 2026 – Market Size, Trends, And
Global Forecast 2026-2035*

LONDON, GREATER LONDON, UNITED
KINGDOM, April 21, 2026

[/EINPresswire.com/](https://www.einpresswire.com/) -- "The [oncology
molecular diagnostics market](#) is

dominated by a mix of global molecular diagnostics corporations, specialized oncology-focused biotechnology companies, and emerging precision medicine technology innovators. Companies are focusing on advanced genomic and proteomic assays, next-generation sequencing-based testing, liquid biopsy platforms, companion diagnostic solutions, and robust regulatory-compliant clinical validation frameworks to strengthen market presence and expand adoption across cancer care and research settings. Understanding the competitive landscape is critical for stakeholders seeking growth opportunities, technological collaborations, and long-term strategic positioning within the rapidly advancing oncology molecular diagnostics market.



Which Market Player Is Leading The Oncology Molecular Diagnostics Market?

- According to our research, F. Hoffmann-La Roche AG led global sales in 2024 with a 58% market share. The diagnostics division of the company is actively involved in the oncology molecular diagnostics market and provides a wide range of genomic and proteomic assays, liquid biopsy platforms, companion diagnostic solutions, and software tools to support precision oncology, clinical decision-making, and regulatory-compliant cancer research environments.

How Concentrated Is The Oncology Molecular Diagnostics Market?

- The market is concentrated, with the top 10 players accounting for 42% of total market revenue in 2024. This level of concentration reflects the oncology molecular diagnostics industry's reliance on advanced genomic technologies, stringent regulatory compliance, high R&D investment requirements, and the need for clinical validation, which create significant barriers to

entry while enabling leading innovators to consolidate market influence and drive adoption across global healthcare environments. Leading vendors such as F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Illumina Inc., Danaher Corp., Abbott Laboratories, Siemens Healthcare AG, QIAGEN N.V., Agilent Technologies, Becton Dickinson and Company, and bioMérieux SA maintain competitive advantage through extensive genomic and molecular diagnostics portfolios, strong clinical laboratory partnerships, integrated workflow solutions, robust regulatory-compliant validation processes, and global distribution networks. At the same time, numerous small and mid-sized specialized diagnostics companies contribute to intense competition, driving rapid innovation, targeted biomarker assays, and cost-effective testing solutions. As adoption of precision oncology and molecular diagnostic technologies accelerates worldwide, strategic collaborations, mergers, and acquisitions are expected to gradually strengthen the position of major players while preserving opportunities for differentiated, outcome-driven solutions across the evolving oncology molecular diagnostics market.

- Leading companies include:
 - o F. Hoffmann-La Roche AG (5%)
 - o Thermo Fisher Scientific Inc. (5%)
 - o Illumina Inc. (5%)
 - o Danaher Corp. (5%)
 - o Abbott Laboratories (4%)
 - o Siemens Healthcare AG (4%)
 - o QIAGEN N.V. (4%)
 - o Agilent Technologies (3%)
 - o Becton Dickinson and Company (3%)
 - o bioMérieux SA (3%)

Request A Free Sample Of The [Oncology Molecular Diagnostics Market Report](https://www.thebusinessresearchcompany.com/sample_request?id=3457&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR)
https://www.thebusinessresearchcompany.com/sample_request?id=3457&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR

Which Companies Are Leading Across Different Regions?

- North America: Geneseeq Technology Inc., Illumina Inc., BioRad Laboratories Inc., Abbott Laboratories, Thermo Fisher Scientific, Roche Diagnostics (F. Hoffmann-La Roche Ltd.), Danaher Corporation and Nanopharmacia Diagnóstica (Mexico City) are leading companies in this region.
- Asia Pacific: BGI Genomics Co., Ltd., Genetron Holdings Limited (Genetron Health), Sysmex Corporation, GeneMatrix Inc., Datar Cancer Genetics (DCGL) Ltd., ACT Genomics Co. Limited, Abbott Diagnostics Australia, Thermo Fisher Scientific Australia, Gene Solutions Genomics Pte Ltd, and QIAGEN are leading companies in this region.
- Western Europe: Caris Life Sciences, Thermo Fisher Scientific UK, Qiagen, Exact Sciences Corporation, Agilent Technologies, Myriad Genetics, OmiCure, Illumina, CeGaT GmbH, Guardant

Health, EDX Medical Group plc, Hedera Dx, DoMore Diagnostics, and SOPHiA GENETICS are leading companies in this region.

- Eastern Europe: MetaCell s.r.o., Sophia Genetics, Genomed SA, Eurofins Genomics, Illumina, NeoGenomics Laboratories, Roche Holding AG, Caris Life Sciences, Thermo Fisher Scientific, Qiagen, Agilent Technologies, Myriad Genetics, and Aignostics are leading companies in this region.

- Middle East: Caris Life Sciences Inc, QIAGEN, Roche, Genoks, M42, SOPHiA GENETICS, Guardant Health, and G42 Healthcare are leading companies in this region.

- Africa: Abbott Laboratories, Geneseeq Technology Inc., Illumina Inc., Thermo Fisher Scientific Inc., Foundation Medicine Inc., Guardant Health Inc., QIAGEN N.V., and Sare are leading companies in this region.

What Are The Major Competitive Trends In The Market?

- Integrated genomic profiling platforms are transforming the oncology molecular diagnostics market by enabling precision medicine, supporting therapy selection, and improving data-driven clinical decisions.
- Example: In July 2025, NeoGenomics, Inc. launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling test expanding its PanTracer portfolio.
- The noninvasive test supports therapy selection, clinical trial matching, and longitudinal monitoring, empowering oncologists to make informed treatment decisions even with limited tumor tissue.

Which Strategies Are Companies Adopting To Stay Ahead?

- Advancing Comprehensive Genomic Profiling And Integrated Assays To Enable Precision Oncology
- Rising Adoption Of RNA-Based Liquid Biopsy And Multiomic Platforms For Noninvasive Diagnostics
- Expanding Liquid Biopsy Genomic Profiling To Support Personalized Treatment Monitoring
- Leveraging Industry 4.0 And Intelligent Manufacturing To Improve Efficiency And Scalability

Access The Detailed Oncology Molecular Diagnostics Market Report Here

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR

Learn More About [The Business Research Company](https://www.thebusinessresearchcompany.com)

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from

interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/907140499>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.